Surge in Little-Known Respiratory Virus HMPV Sparks Public Health Alarms as Cases Rise Sharply

A little-known respiratory virus is sweeping across the United States, drawing fresh scrutiny from public health experts and raising alarms in major urban centers. Human metapneumovirus, or HMPV, has been surging since fall 2025, with wastewater surveillance data revealing a widespread presence from the West Coast to the Northeast. By the first week of March, the CDC reported that HMPV accounted for over five percent of all positive respiratory virus tests nationwide—a sharp rise from 3.8 percent in the final week of February. This uptick has prompted health officials to issue urgent advisories, particularly as no vaccine or fully effective treatment currently exists for the virus.

First identified in 2001, HMPV belongs to the same viral family as respiratory syncytial virus (RSV), which typically causes mild respiratory symptoms lasting about a week. Yet, HMPV has emerged as a growing concern, with its resurgence now outpacing previous patterns. Dr. Tyler B. Evans, an infectious diseases physician and CEO of Wellness Equity Alliance, emphasized that while the virus is not new, its impact on vulnerable populations is undeniable. "For the general public, HMPV is rarely a serious threat," he explained. "But for infants under two, adults over 65, and those with weakened immune systems or chronic lung conditions, it can escalate to severe lower respiratory tract disease, particularly in crowded settings like shelters and nursing homes."

The current surge marks at least the second major HMPV outbreak since the start of the pandemic, following a notable spike in 2023. Seasonal trends suggest the virus typically peaks in March or April, with the most recent surge in Spring 2025 reaching a test positivity rate of 7.4 percent in April. The earlier 2023 wave saw even higher positivity at 11 percent. However, health officials caution that these figures likely underrepresent the true scale of the outbreak, as many infected individuals with mild symptoms avoid seeking medical care. Most people encounter HMPV during childhood and may experience multiple infections without ever realizing it, according to the American Medical Association.

Symptoms of HMPV closely mirror those of a severe cold or flu, including cough, fever, nasal congestion, sore throat, and shortness of breath. The CDC notes that most people remain infectious for one to two weeks after symptoms begin, with recovery typically occurring within seven days. For the general population, the mortality rate aligns with that of the flu and RSV—hovering around 1 percent. However, the risk for infants and immunocompromised individuals is starkly higher, with a 43 percent chance of dying from pneumonia caused by the virus.

Health officials stress that most cases can be managed at home with rest, hydration, and over-the-counter fever reducers. The virus spreads through respiratory droplets, close contact, and contaminated surfaces, making simple precautions like handwashing and staying home when sick critical to slowing transmission. Unlike the flu or RSV, no vaccine exists for HMPV, leaving prevention efforts focused on limiting exposure. When symptoms progress to difficulty breathing, chest pain, or inability to retain fluids, immediate medical attention is essential.

Public health advisories urge vigilance, particularly in high-risk communities. While the virus may not be exotic, its persistence and potential for severe complications demand continued monitoring and targeted interventions. As the season progresses, officials warn that the next few months could see further spikes, underscoring the need for preparedness and adherence to basic hygiene measures. For now, the message is clear: HMPV may not be new, but its threat remains very real.

Public health officials are urging heightened caution as human metapneumovirus (HMPV) cases surge nationwide, with recent data revealing a sharp increase in infections. According to Centers for Disease Control and Prevention (CDC) reports, HMPV accounted for over five percent of all positive respiratory test results during the first week of March—a marked jump from earlier this year. This trend has prompted experts to reiterate foundational prevention strategies: frequent handwashing, surface disinfection, mask-wearing in crowded spaces, and avoiding close contact with symptomatic individuals. These measures, though seemingly simple, are critical for curbing transmission, especially as HMPV continues to circulate alongside other respiratory viruses.

Healthcare professionals emphasize that the virus typically incubates for three to six days before symptoms emerge, making early intervention challenging. Dr. Evans, a leading infectious disease specialist, stressed that vigilance is particularly crucial for households with young children, elderly relatives, or immunocompromised individuals. "While HMPV isn't uniquely more dangerous than other viruses, its impact can be severe in these vulnerable groups," he said. This underscores the importance of proactive measures, such as isolating sick household members and prioritizing hygiene in shared spaces like kitchens and bathrooms.

Despite the rising case numbers, diagnostic testing for HMPV remains underutilized in many clinical settings. The CDC noted that healthcare providers often do not routinely test for the virus, as there are no targeted treatments or vaccines available. However, testing can still play a vital role in distinguishing HMPV from other infections like influenza or respiratory syncytial virus (RSV). This distinction is essential for guiding decisions on isolation protocols, antibiotic use, and whether further diagnostic tests are needed.

Currently, medical care for HMPV focuses on supportive treatment rather than curative interventions. Doctors recommend rest, hydration, and over-the-counter medications such as acetaminophen or ibuprofen to manage fever and discomfort. Patients are advised to stay home to avoid spreading the virus, a measure that public health officials say can significantly reduce community transmission. As HMPV continues to evolve as a public health concern, experts warn that complacency could lead to preventable complications, particularly among at-risk populations.

With no antiviral drugs or vaccines in development for HMPV, the onus remains on individual and collective action to mitigate its spread. Public health campaigns are now emphasizing the importance of these basic precautions, framing them as a frontline defense against both this virus and others that may emerge in the future. As Dr. Evans concluded, "The tools we have are effective—but only if we use them consistently.